Építés alatt – nem éles oldal
Belépés
Leállítva2. fázis

Elotuzumab in Immunoglobulin G4-Related Disease (IgG4-RD)

A legfontosabb adatok

Ki végzi
National Institute of Allergy and Infectious Diseases (NIAID)
Hol
Atlanta, Boston és Rochester (Egyesült Államok)Mind a 3 helyszín megnézése
Azonosító
Állapot
Leállítva
Fázis
2. fázis
Résztvevők
8 fő vett részt
Kezdés
2021. okt. 13.
Befejezés
2024. jan. 4.
A vizsgálat típusa
Beavatkozással járó, 4 csoportAz egyik csoport placebót (hatóanyag nélküli szert) kap, összehasonlításként.
A vizsgált kezelések
  • elotuzumab
  • placebo for elotuzumab
  • methylprednisolone
  • diphenhydramine
  • acetaminophen
  • famotidine
  • prednisone
A regiszteradat frissítve
2026. február 5.
Miért állt le
The study was terminated early based on disease flare/lack of efficacy in the early phase of the trial.

Ki vehet részt

Életkor
18 év – 70 év
Nem
Nők és férfiak
Egészséges önkéntesek
Nem vehetnek részt

A regiszter feltételei, szó szerint

Mind a 28 feltétel megnézéseKevesebb

Ki vehet részt

  • Individuals who meet all of the following criteria are eligible for enrollment as study participants:
  • Participant must be able to understand and provide informed consent and be willing to comply with study procedures and follow up
  • Are at least 18 years of age and not older than 70 years of age at screening
  • Meet the ACR/EULAR Classification Criteria for IgG4-RD [30, 31]
  • Have active disease based at screening on an IgG4-RD RI ≥4, with disease manifestations in at least two organ systems
  • May have newly-diagnosed or relapsing disease at screening. Relapsing disease is defined as IgG4-RD that has previously been in remission but is now active again
  • May be on treatment or off treatment for IgG4-RD at the time of screening. If on treatment, must be willing to discontinue those other treatments before the baseline visit
  • No history of severe allergic reactions to monoclonal antibodies
  • Female participants of childbearing potential must have a negative pregnancy test upon study entry
  • Female participants of childbearing potential and male participants with a partner of childbearing potential must agree to consistently and correctly use FDA approved highly effective methods of birth control for the entire duration of the study and 6 months after last elotuzumab infusion
  • Immunization with one of the FDA authorized or licensed SARS-CoV-2 vaccines as per CDC recommendations at the time of informed consent is required for study entry. Vaccinations must have been completed at least 2 weeks prior to start of study therapy

Ki nem vehet részt

  • Active infection requiring hospitalization or treatment with systemic antimicrobial agents within the 30 days prior to treatment allocation/randomization
  • Prior use of rituximab or other B cell depleting agents within 9 months of enrollment unless B cells have been demonstrated to have repopulated
  • Use of any investigational agent or biologic and non-biologic DMARDs within 5 half-lives of the agent (or 6 months if the half-life is unknown) prior to enrollment
  • At or within 90 days of screening: Positive Interferon-Gamma Release Assay (IGRA). Indeterminate IGRAs must be repeated (with same or other IGRA per local policy) and shown to be negative. Alternatively, if the assay remains indeterminant, a participant must have a negative PPD. Finally, if the participant has had the Bacille Calmette-Guerin (BCG) vaccine or has some other condition complicating the interpretation of TB testing, consultation with infectious disease specialist must be obtained before receipt of the first investigational infusion; Participants diagnosed with latent TB are eligible but must have received appropriate prophylaxis for 30 days before their first investigational infusion
  • Live vaccines within 8 weeks of initiating study therapy
  • Evidence a SARS-CoV-2 (COVID-19) infection started within the 30 days prior to treatment allocation/randomization. Participants diagnosed with SARS-CoV-2 (COVID-19) infection more than 30 days prior to treatment allocation/randomization must have symptoms resolved and be deemed fit to participate in the trial
  • Presence of a condition other than IgG4-RD that (e.g., asthma) is likely to require systemic Glucocorticoids (GC) for disease control during the period of the trial
  • Malignancy within 5 years (except successfully treated in situ cervical cancer, resected squamous cell or basal cell carcinoma of the skin.)
  • Evidence of another uncontrolled condition which, in the judgment of the investigator, could interfere with participation in the trial according to the protocol
  • Medical history or serologic evidence at Screening of chronic infections including:; Human immunodeficiency virus infection; Hepatitis B as indicated by surface antigen or hepatitis B core antibody positivity; Hepatitis C as indicated by anti-hepatitis C antibody positivity; if a participant is Hepatitis C antibody positive, they will be eligible to participate in the study if he/she is negative for viral load at Screening
  • Substance use disorder, including the recurrent use of alcohol and/or drugs within the past year associated with clinically significant impairment associated with failure to meet major responsibilities at work, school, or home
  • IgG4-RD that is dominated primarily by advanced fibrotic lesions. Specifically, participants whose disease manifestations consist only of; retroperitoneal fibrosis,; fibrosing mediatinitis,; sclerosing mesenteritis, or; Riedel's thyroiditis. Participants with these disease manifestations can be included, however, only if they have disease in 2 organ systems that is not of an advanced fibrotic nature and otherwise meet the Inclusion and Exclusion Criteria
  • The following lab values as indicators of hepatic dysfunction:; Serum aspartate aminotransferase (AST) or alanine aminotransferase (ALT) greater than three times the upper limit of normal (ULN); Total bilirubin > two times the ULN unless caused by Gilbert's disease. Gilbert's disease with total bilirubin > three times ULN; Serum albumin < 2.5 gm/dL
  • Any of the following laboratory tests at the Screening Visit:; White blood cell count (WBC) < 3.0 x 103/µL; Absolute neutrophil count (ANC) < 1.5 x 103/µL; Hemoglobin < 10 g/dL; Platelet count < 75 x 109/L; Estimated glomerular filtration rate (eGFR) ≤ 45 ml/minute/1.73 m2
  • Individuals who meet any of these criteria are not eligible for enrollment as study participants:
  • The use of supplemental oxygen at baseline
  • Participant is pregnant or breastfeeding, or planning a pregnancy while enrolled in the study

Helyszínek itt: Egyesült Államok

  • Emory HealthcareAtlanta, Egyesült Államok
  • Massachusetts General HospitalBoston, Egyesült Államok
  • Mayo Clinic: Pulmonary and Critical Care MedicineRochester, Egyesült Államok

A vizsgálatról

Mit akar kideríteni a vizsgálat

This is a two-part multi-center clinical trial in participants with active IgG4-RD.

A teljes eredeti leírásKevesebb

Part 1 (Cohort 1a and Cohort 1B) is an open-label, dose escalation phase to determine the safety of elotuzumab for investigation in IgG4-RD.

Part 2 (Cohort 2) is a randomized, placebo-controlled, double-blinded (masked) trial phase to compare the effects of elotuzumab and prednisone to elotuzumab placebo and prednisone in participants with IgG4 RD.

Approximately 75 participants with active IgG4-RD will be enrolled in the overall program, 12 in Part 1 and 63 in Part 2. Randomization in Part 2: 2 to 1, with approximately forty-two participants randomized to elotuzumab plus prednisone taper, and twenty-one participants randomized to placebo for elotuzumab plus prednisone taper.

The total duration of participation for each participant in this trial will be 48 weeks (11 months).

A vizsgálat 4 csoportja

  • Cohort 1a: Elotuzumab-One-Month Regimen (Open-Label) + Pred TaperA vizsgált kezelés

    Per protocol: Six participants will receive elotuzumab on days 0,7, 14, 21, and the prescribed 10-week prednisone taper. * Elotuzumab: 10 mg/kg administered once weekly, intravenously for 4 doses, per protocol. * Prednisone taper (Pred Taper): Prescribed 10-week dosing taper beginning on Day 0 (baseline) that is taken orally (by mouth) daily, per protocol. Dosage in milligrams (mgs).

    Kezelés: elotuzumab, methylprednisolone, diphenhydramine, acetaminophen, famotidine és prednisone

  • Cohort 1b: Elotuzumab-Twelve-Month Regimen (Open-Label) + Pred TaperA vizsgált kezelés

    Per protocol: Six participants will receive elotuzumab over a 48 week period, dose of 10mg/kg IV x 1, at baseline, then at weeks 8, 16, 24, 32 and 40 (for a total of 6 doses), with the prescribed 10-week prednisone taper. * Elotuzumab: 10 mg/kg administered as referenced above, intravenously, per protocol. * Prednisone taper (Pred Taper): Prescribed 10-week dosing taper beginning on Day 0 (baseline) that is taken orally (by mouth) daily, per protocol. Dosage in milligrams (mgs).

    Kezelés: elotuzumab, methylprednisolone, diphenhydramine, acetaminophen, famotidine és prednisone

  • Cohort 2: Arm A- Elotuzumab (Randomized) + Pred TaperA vizsgált kezelés

    Safety and efficacy analyses from Cohort 1a and Cohort 1b will occur prior to initiating Cohort 2 (Randomized). Assuming no safety signal for Cohort 1, forty-two participants will receive elotuzumab per the regimen prescribed above in Part 1B, with the prescribed 10-week prednisone taper. * Elotuzumab: 10 mg/kg administered as referenced above, intravenously, per protocol. * Prednisone taper (Pred Taper): Prescribed 10-week dosing taper beginning on Day 0 that is taken daily by mouth, per protocol. Dosage in milligrams (mgs).

    Kezelés: elotuzumab, methylprednisolone, diphenhydramine, acetaminophen, famotidine és prednisone

  • Cohort 2: Arm B-Placebo (Randomized) + Pred TaperPlacebo, összehasonlításként

    Safety and efficacy analyses from Cohort 1a and Cohort 1b will occur prior to initiating Cohort 2 (Randomized). Twenty-one participants will receive placebo for elotuzumab on day 0, then weeks 8, 16, 24, 32 and 40, and the prescribed 10-week prednisone taper. * Placebo for elotuzumab: Administered on same schedule as elotuzumab described in Cohort 2 Arm A: intravenously, per protocol. * Prednisone taper (Pred Taper): Prescribed 10-week dosing taper beginning on Day 0 taken daily by mouth, per protocol. Dosage in milligrams (mgs).

    Kezelés: placebo for elotuzumab, methylprednisolone, diphenhydramine, acetaminophen, famotidine és prednisone

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
A regiszteradat frissítve
2026. február 5.